AU2016239270B2 - Imidazolonyl quinolines and use thereof as ATM kinase inhibitors - Google Patents

Imidazolonyl quinolines and use thereof as ATM kinase inhibitors Download PDF

Info

Publication number
AU2016239270B2
AU2016239270B2 AU2016239270A AU2016239270A AU2016239270B2 AU 2016239270 B2 AU2016239270 B2 AU 2016239270B2 AU 2016239270 A AU2016239270 A AU 2016239270A AU 2016239270 A AU2016239270 A AU 2016239270A AU 2016239270 B2 AU2016239270 B2 AU 2016239270B2
Authority
AU
Australia
Prior art keywords
methyl
pyrazol
methoxy
quinolin
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016239270A
Other languages
English (en)
Other versions
AU2016239270A1 (en
Inventor
Thomas Fuchss
Kai Schiemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2016239270A1 publication Critical patent/AU2016239270A1/en
Application granted granted Critical
Publication of AU2016239270B2 publication Critical patent/AU2016239270B2/en
Priority to AU2020204241A priority Critical patent/AU2020204241B2/en
Priority to AU2022256215A priority patent/AU2022256215A1/en
Priority to AU2025200385A priority patent/AU2025200385A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2016239270A 2015-04-02 2016-03-31 Imidazolonyl quinolines and use thereof as ATM kinase inhibitors Active AU2016239270B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2020204241A AU2020204241B2 (en) 2015-04-02 2020-06-25 Imidazolonyl quinolines and use thereof as ATM kinase inhibitors
AU2022256215A AU2022256215A1 (en) 2015-04-02 2022-10-21 Imidazolonyl quinolines and use thereof as ATM kinase inhibitors
AU2025200385A AU2025200385A1 (en) 2015-04-02 2025-01-20 Imidazolonyl quinolines and use thereof as ATM kinase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15000968 2015-04-02
EP15000968.6 2015-04-02
PCT/EP2016/000542 WO2016155884A1 (de) 2015-04-02 2016-03-31 Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020204241A Division AU2020204241B2 (en) 2015-04-02 2020-06-25 Imidazolonyl quinolines and use thereof as ATM kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2016239270A1 AU2016239270A1 (en) 2017-11-16
AU2016239270B2 true AU2016239270B2 (en) 2020-03-26

Family

ID=52814780

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2016239270A Active AU2016239270B2 (en) 2015-04-02 2016-03-31 Imidazolonyl quinolines and use thereof as ATM kinase inhibitors
AU2020204241A Active AU2020204241B2 (en) 2015-04-02 2020-06-25 Imidazolonyl quinolines and use thereof as ATM kinase inhibitors
AU2022256215A Abandoned AU2022256215A1 (en) 2015-04-02 2022-10-21 Imidazolonyl quinolines and use thereof as ATM kinase inhibitors
AU2025200385A Pending AU2025200385A1 (en) 2015-04-02 2025-01-20 Imidazolonyl quinolines and use thereof as ATM kinase inhibitors

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2020204241A Active AU2020204241B2 (en) 2015-04-02 2020-06-25 Imidazolonyl quinolines and use thereof as ATM kinase inhibitors
AU2022256215A Abandoned AU2022256215A1 (en) 2015-04-02 2022-10-21 Imidazolonyl quinolines and use thereof as ATM kinase inhibitors
AU2025200385A Pending AU2025200385A1 (en) 2015-04-02 2025-01-20 Imidazolonyl quinolines and use thereof as ATM kinase inhibitors

Country Status (24)

Country Link
US (5) US10457677B2 (enExample)
EP (3) EP3868761B1 (enExample)
JP (2) JP6791873B2 (enExample)
KR (2) KR20240044525A (enExample)
CN (3) CN107889488B (enExample)
AU (4) AU2016239270B2 (enExample)
BR (1) BR122019005502B1 (enExample)
CA (1) CA2981365A1 (enExample)
DK (2) DK3277681T3 (enExample)
ES (3) ES2741853T3 (enExample)
HR (2) HRP20191396T1 (enExample)
HU (2) HUE045477T2 (enExample)
IL (3) IL254714B (enExample)
LT (2) LT3560924T (enExample)
MX (2) MX390537B (enExample)
PL (2) PL3277681T3 (enExample)
PT (2) PT3277681T (enExample)
RS (2) RS62082B1 (enExample)
RU (1) RU2743343C2 (enExample)
SG (2) SG11201708065QA (enExample)
SI (2) SI3277681T1 (enExample)
TR (1) TR201911244T4 (enExample)
WO (1) WO2016155884A1 (enExample)
ZA (1) ZA201707423B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11730836B2 (en) 2018-01-12 2023-08-22 Prolynx Llc Synergistic cancer treatment
WO2024112796A1 (en) * 2022-11-23 2024-05-30 Forward Therapeutics, Inc. MODULATORS OF TNF-α ACTIVITY

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107889488B (zh) * 2015-04-02 2020-08-11 默克专利股份公司 咪唑酮基喹啉和其作为atm激酶抑制剂的用途
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US11547703B2 (en) 2017-02-27 2023-01-10 Impact Therapeutics (Shanghai), Inc Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
RU2020133020A (ru) * 2018-03-14 2022-04-14 Мерк Патент Гмбх Соединения и их применения для лечения опухолей у субъекта
EP3904350B1 (en) 2018-04-12 2023-08-23 Bayer Aktiengesellschaft N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
GB201814487D0 (en) * 2018-09-06 2018-10-24 Cycle Pharmaceuticals Ltd Cancer
CN109045042A (zh) * 2018-09-21 2018-12-21 上海交通大学医学院附属上海儿童医学中心 Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用
KR102345208B1 (ko) 2018-09-30 2021-12-30 메드샤인 디스커버리 아이엔씨. 퀴놀리노-피롤리딘-2-온 유도체 및 이의 응용
JP2022526926A (ja) 2019-03-27 2022-05-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング イミダゾロニルキノリン化合物およびそれらの治療への使用
EP4003345B1 (en) * 2019-07-30 2024-12-04 XRad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
JP2023501971A (ja) * 2019-11-01 2023-01-20 アレス トレーディング ソシエテ アノニム 癌の治療のための、放射線療法と共に用いるＰＤ－１、ＴＧＦβ、及びＡＴＭの組み合わせ阻害
WO2021113506A1 (en) * 2019-12-04 2021-06-10 Chdi Foundation, Inc. Atm kinase inhibitors and compositions and methods of use thereof
WO2021139814A1 (zh) * 2020-01-09 2021-07-15 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
WO2021197339A1 (zh) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
JP2023530004A (ja) * 2020-06-18 2023-07-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルス感染症の処置のための化合物
TW202216209A (zh) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atm抑制劑之組合
US20230330027A1 (en) 2020-09-18 2023-10-19 Merck Patent Gmbh Pharmaceutical preparation
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
CN115232122B (zh) * 2021-04-23 2024-05-31 石药集团中奇制药技术（石家庄）有限公司 炔类化合物及其制备和应用
CN115716829B (zh) * 2022-11-13 2024-05-31 药康众拓(江苏)医药科技有限公司 一种喹啉并咪唑酮联氘代吡唑类化合物及其应用
WO2025157979A1 (en) 2024-01-26 2025-07-31 Merck Patent Gmbh Synthesis route for preparing 8-(1,3-dimethyl-1h-pyrazol-4-yl)-1-(sa)-(3-fluoro-5-methoxy-pyridin-4-yl)-7-methoxy-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010139731A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
WO2011054846A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Imidazo [4, 5-c] quinoline derivates as bromodomain inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2193921T3 (es) * 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
BRPI0609399A2 (pt) 2005-03-21 2010-03-30 Ferrer Int método para produzir compostos da 1h-imidazo[4,5-c]quinolin-4-amina 1-substituìda e intermediários dos mesmos
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7598273B2 (en) * 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
CN101616672A (zh) 2007-02-20 2009-12-30 诺瓦提斯公司 作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类
RU2509558C2 (ru) 2008-03-26 2014-03-20 Новартис Аг Имидазохинолины и производные пиримидина в качестве потенциальных модуляторов vegf-стимулируемых ангиогенных процессов
UY31881A (es) 2008-06-10 2010-01-29 Abbott Lab Derivados sustituidos de imidazo[1,5-a]pirrolo[2,3-e]pirazinas e imidazo[1,2-a]pirrolo[2,3-e]pirazinas, sus sales, prodrogas, metabolitos biológicalmente activos, estereoisómeros e isómeros farmacéuticamente aceptables.
CN102170873B (zh) 2008-10-01 2014-07-30 诺华股份有限公司 用于治疗与hedgehog通路有关的病症的smoothened拮抗
US20100311714A1 (en) 2009-06-04 2010-12-09 Pascal Furet 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS
WO2011113512A1 (de) * 2010-03-16 2011-09-22 Merck Patent Gmbh Morpholinylchinazoline
CN102958930B (zh) * 2010-06-28 2018-04-27 默克专利有限公司 作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物
CN102372711B (zh) 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
MA34806B1 (fr) 2010-12-03 2014-01-02 Novartis Ag Compositions pharmaceutiques
CN103012398B (zh) 2011-09-19 2015-10-14 上海恒瑞医药有限公司 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
US9879003B2 (en) 2012-04-11 2018-01-30 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
BR112014030099A2 (pt) 2012-06-06 2017-06-27 Novartis Ag combinação de um inibidor 17-alfa-hidroxilase(c17,20-liase) e um inibidor pi-3 k específico para tratamento de uma doença de tumor
NO2714752T3 (enExample) 2014-05-08 2018-04-21
CN107889488B (zh) 2015-04-02 2020-08-11 默克专利股份公司 咪唑酮基喹啉和其作为atm激酶抑制剂的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010139731A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
WO2011054846A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Imidazo [4, 5-c] quinoline derivates as bromodomain inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11730836B2 (en) 2018-01-12 2023-08-22 Prolynx Llc Synergistic cancer treatment
WO2024112796A1 (en) * 2022-11-23 2024-05-30 Forward Therapeutics, Inc. MODULATORS OF TNF-α ACTIVITY
US12384808B2 (en) 2022-11-23 2025-08-12 Forward Therapeutics, Inc. Modulators of TNF-α activity

Also Published As

Publication number Publication date
EP3560924A1 (de) 2019-10-30
AU2022256215A1 (en) 2022-11-24
TR201911244T4 (tr) 2019-08-21
CN111689963A (zh) 2020-09-22
NZ736641A (en) 2024-09-27
ES2946507T3 (es) 2023-07-20
PT3277681T (pt) 2019-08-20
MX390537B (es) 2025-03-20
MX2017012613A (es) 2018-01-24
US10745399B2 (en) 2020-08-18
AU2020204241B2 (en) 2022-11-17
ES2880626T3 (es) 2021-11-25
US20200325137A1 (en) 2020-10-15
RU2017138100A3 (enExample) 2019-10-04
AU2016239270A1 (en) 2017-11-16
HUE045477T2 (hu) 2019-12-30
DK3277681T3 (da) 2019-07-29
US20180072715A1 (en) 2018-03-15
KR20170132323A (ko) 2017-12-01
JP7111790B2 (ja) 2022-08-02
HRP20210981T1 (hr) 2021-09-17
IL254714B (en) 2020-01-30
IL282584A (en) 2021-06-30
HRP20191396T1 (hr) 2019-11-01
CN111747952A (zh) 2020-10-09
EP3560924B1 (de) 2021-03-31
LT3277681T (lt) 2019-08-12
PT3560924T (pt) 2021-07-02
RS62082B1 (sr) 2021-08-31
RU2743343C2 (ru) 2021-02-17
CA2981365A1 (en) 2016-10-06
MX376947B (es) 2025-03-07
DK3560924T3 (da) 2021-06-28
ZA201707423B (en) 2021-05-26
SG10202002181UA (en) 2020-05-28
EP3277681B1 (de) 2019-05-08
LT3560924T (lt) 2021-08-25
IL282584B (en) 2021-12-01
AU2020204241A1 (en) 2020-07-16
JP2021046403A (ja) 2021-03-25
US20190211013A1 (en) 2019-07-11
NZ774407A (en) 2024-09-27
CN107889488B (zh) 2020-08-11
US10975075B2 (en) 2021-04-13
SI3277681T1 (sl) 2019-09-30
US10457677B2 (en) 2019-10-29
US20210198257A1 (en) 2021-07-01
EP3277681A1 (de) 2018-02-07
SI3560924T1 (sl) 2021-08-31
ES2741853T3 (es) 2020-02-12
MX2020011558A (es) 2022-03-09
KR102652052B1 (ko) 2024-03-27
RU2017138100A (ru) 2019-05-08
PL3277681T3 (pl) 2019-10-31
BR112017020941A2 (pt) 2018-07-10
HUE054745T2 (hu) 2021-09-28
SG11201708065QA (en) 2017-10-30
JP6791873B2 (ja) 2020-11-25
PL3560924T3 (pl) 2021-10-11
WO2016155884A1 (de) 2016-10-06
IL271494A (en) 2020-02-27
JP2018510191A (ja) 2018-04-12
AU2025200385A1 (en) 2025-02-13
IL254714A0 (en) 2017-11-30
KR20240044525A (ko) 2024-04-04
US11608338B2 (en) 2023-03-21
EP3868761A1 (de) 2021-08-25
BR122019005502B1 (pt) 2024-02-27
EP3868761B1 (de) 2023-03-01
US20230203034A1 (en) 2023-06-29
IL271494B (en) 2021-05-31
CN107889488A (zh) 2018-04-06
RS59139B1 (sr) 2019-09-30

Similar Documents

Publication Publication Date Title
AU2020204241B2 (en) Imidazolonyl quinolines and use thereof as ATM kinase inhibitors
JP6133291B2 (ja) ピラゾロ［３，４−ｃ］ピリジン化合物と使用方法
KR102292811B1 (ko) 아릴퀴나졸린
KR101912475B1 (ko) Ｄｎａ-ｐｋ 저해제로서의 이미다조［4,5-ｃ］퀴놀린
ES2661256T3 (es) Derivados de 3-cianaril-1H-pirrolo[2,3-b]piridina
EA020715B1 (ru) ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА
US9284315B2 (en) Three-ring PI3K and/or mTOR inhibitor
AU2012339196A1 (en) Morpholinyl benzotriazine for use in cancer therapy
BR112017020941B1 (pt) Imidazolonilquinolinas, seus usos, composições farmacêuticas, e kit

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)